New combo therapy aims to halt lung cancer spread in its tracks

NCT ID NCT07379476

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jan 31, 2026 · Last updated May 22, 2026 · Updated 22 times

Summary

This study tests whether adding local ablative therapy (such as radiation) to the standard drug osimertinib can better control advanced EGFR-mutant lung cancer. About 64 adults with stage IV non-small cell lung cancer and up to 3 remaining active tumor sites after 3-6 months of osimertinib will be randomly assigned to continue the drug alone or add local therapy. The main goal is to see if the combination improves the chance of staying cancer-free for 18 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Clinical Oncology, Prince of Wales Hospital
RECRUITING

Hong Kong, Hong Kong

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

LUNG CANCER (NSCLC)